Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

Source: Financial Post· GlobeNewswire· July 29, 2026
SynaBot summary

The FDA has cleared Smith+Nephew's TESSA Spatial Surgery System, a new AI-powered tool for sports medicine. This system uses advanced computing to enable personalized surgical planning and procedural innovation, marking a significant advancement in the field.

Key takeaways

  • FDA grants De Novo classification for TESSA Spatial Surgery System
  • AI system enhances personalized surgical planning in sports medicine
  • Commercial launch planned for Q3 2026 with wider deployment in 2027

Why it matters

This FDA clearance signifies a leap forward in AI's application within healthcare, specifically surgery. For AI tool users, it highlights how sophisticated AI is becoming for complex, real-world problem-solving, potentially influencing future medical AI development.

This story was reported by Financial Post. Read the full original article:
Read on Financial Post

Try this on SynaBot

Related AI assistants, prompts, and tools from the SynaBot catalog.

More in Products & Launches

View all